ArticleCancer management and research2021

Efficacy and Prognosis of First-Line EGFR-Tyrosine Kinase Inhibitor Treatment in Older Adults Including Poor Performance Status Patients with

Cheng-Yu Chang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.